IL289763A - Compounds, pharmaceutical compounds and methods for preparing compounds and their use - Google Patents
Compounds, pharmaceutical compounds and methods for preparing compounds and their useInfo
- Publication number
- IL289763A IL289763A IL289763A IL28976322A IL289763A IL 289763 A IL289763 A IL 289763A IL 289763 A IL289763 A IL 289763A IL 28976322 A IL28976322 A IL 28976322A IL 289763 A IL289763 A IL 289763A
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- preparing
- preparing compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877177P | 2019-07-22 | 2019-07-22 | |
| PCT/CA2019/051539 WO2020087170A1 (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| PCT/CA2020/051014 WO2021012049A1 (en) | 2019-07-22 | 2020-07-22 | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289763A true IL289763A (en) | 2022-03-01 |
Family
ID=74192632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289763A IL289763A (en) | 2019-07-22 | 2022-01-11 | Compounds, pharmaceutical compounds and methods for preparing compounds and their use |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220185809A1 (https=) |
| EP (1) | EP4003993A4 (https=) |
| JP (2) | JP7617076B2 (https=) |
| KR (1) | KR20220035925A (https=) |
| CN (1) | CN114174292B (https=) |
| AU (1) | AU2020317381A1 (https=) |
| BR (1) | BR112022000431A2 (https=) |
| CA (1) | CA3148278A1 (https=) |
| CO (1) | CO2022001853A2 (https=) |
| CR (1) | CR20220068A (https=) |
| EC (1) | ECSP22012347A (https=) |
| IL (1) | IL289763A (https=) |
| MX (1) | MX2022000854A (https=) |
| PH (1) | PH12022550156A1 (https=) |
| UA (1) | UA129807C2 (https=) |
| WO (1) | WO2021012049A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20210281A (es) | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
| CA3164203A1 (en) * | 2019-12-11 | 2021-06-17 | Repare Therapeutics Inc. | Use of atr inhibitors in combination with parp inhibitors |
| BR112023022481A2 (pt) * | 2021-04-28 | 2024-02-15 | Repare Therapeutics Inc | Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica |
| MX2023014302A (es) * | 2021-06-04 | 2024-02-28 | Repare Therapeutics Inc | Formas cristalinas, composiciones que contienen las mismas y métodos para su uso. |
| KR20240041354A (ko) * | 2021-07-27 | 2024-03-29 | 릿츠뜨 메디시네스 엘티디 | 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 |
| CN113856764B (zh) * | 2021-10-29 | 2022-11-01 | 华中科技大学 | 一种过渡金属催化剂及其制备方法和应用 |
| CN116099390B (zh) * | 2022-11-14 | 2024-07-23 | 石河子大学 | 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用 |
| WO2024211696A1 (en) * | 2023-04-07 | 2024-10-10 | Biogen Ma Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025067111A1 (zh) * | 2023-09-27 | 2025-04-03 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025181153A1 (en) * | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202545519A (zh) * | 2024-05-15 | 2025-12-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795573B1 (en) * | 2009-12-31 | 2022-07-06 | Hutchison Medipharma Limited | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| JP5889875B2 (ja) * | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| ES2951688T3 (es) * | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013095761A1 (en) * | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
| TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| RS61688B1 (sr) * | 2015-04-29 | 2021-05-31 | Janssen Pharmaceutica Nv | Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora |
| JP6873145B2 (ja) * | 2016-01-14 | 2021-05-19 | バイエル・ファルマ・アクティエンゲゼルシャフト | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン |
| CR20210281A (es) * | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
-
2020
- 2020-07-22 MX MX2022000854A patent/MX2022000854A/es unknown
- 2020-07-22 UA UAA202200734A patent/UA129807C2/uk unknown
- 2020-07-22 CN CN202080052942.8A patent/CN114174292B/zh active Active
- 2020-07-22 CA CA3148278A patent/CA3148278A1/en active Pending
- 2020-07-22 BR BR112022000431A patent/BR112022000431A2/pt unknown
- 2020-07-22 EP EP20843290.6A patent/EP4003993A4/en active Pending
- 2020-07-22 JP JP2022504181A patent/JP7617076B2/ja active Active
- 2020-07-22 AU AU2020317381A patent/AU2020317381A1/en not_active Abandoned
- 2020-07-22 KR KR1020227004829A patent/KR20220035925A/ko not_active Ceased
- 2020-07-22 CR CR20220068A patent/CR20220068A/es unknown
- 2020-07-22 WO PCT/CA2020/051014 patent/WO2021012049A1/en not_active Ceased
- 2020-07-22 PH PH1/2022/550156A patent/PH12022550156A1/en unknown
-
2022
- 2022-01-11 IL IL289763A patent/IL289763A/en unknown
- 2022-01-20 US US17/580,207 patent/US20220185809A1/en active Pending
- 2022-02-16 EC ECSENADI202212347A patent/ECSP22012347A/es unknown
- 2022-02-22 CO CONC2022/0001853A patent/CO2022001853A2/es unknown
-
2025
- 2025-01-06 JP JP2025001996A patent/JP7758895B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022541825A (ja) | 2022-09-27 |
| JP2025061048A (ja) | 2025-04-10 |
| MX2022000854A (es) | 2022-02-10 |
| ECSP22012347A (es) | 2022-03-31 |
| CA3148278A1 (en) | 2021-01-28 |
| CR20220068A (es) | 2022-06-30 |
| KR20220035925A (ko) | 2022-03-22 |
| AU2020317381A1 (en) | 2022-02-10 |
| BR112022000431A2 (pt) | 2022-03-03 |
| UA129807C2 (uk) | 2025-08-06 |
| WO2021012049A8 (en) | 2021-04-15 |
| EP4003993A4 (en) | 2023-01-18 |
| EP4003993A1 (en) | 2022-06-01 |
| CN114174292B (zh) | 2024-06-18 |
| PH12022550156A1 (en) | 2023-05-08 |
| WO2021012049A1 (en) | 2021-01-28 |
| CO2022001853A2 (es) | 2022-03-29 |
| US20220185809A1 (en) | 2022-06-16 |
| JP7617076B2 (ja) | 2025-01-17 |
| CN114174292A (zh) | 2022-03-11 |
| JP7758895B2 (ja) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
| SG11202104460UA (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| IL282822B1 (en) | Pharmaceutical preparations containing cannabinoid analogues, their use and methods for their preparation | |
| SG11202105850YA (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
| IL288278A (en) | Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith | |
| IL278829A (en) | The compositions containing bis-(fluoroalkyl)-1,4 benzodiazepines and immunotherapeutic substances and methods of using them | |
| SG11202105730TA (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| SG11202111701XA (en) | Coated drug compositions and methods of preparing the same | |
| IL271807A (en) | New compounds and their pharmaceutical preparations for the treatment of leprosy | |
| IL292668B1 (en) | Tricyclic derivative of dihydroimidazopyrimidone, method of preparation thereof, pharmaceutical preparation and use thereof | |
| EP3279207A4 (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
| IL276290A (en) | Heteroaryl compounds, their pharmaceutical preparations and their medical use | |
| SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| IL274123A (en) | Co-crystals, their pharmaceutical preparations and treatment methods involving them | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| EP3284743A4 (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
| EP3647313A4 (en) | SUBSTITUTED ARYLETHER COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| IL272284B1 (en) | History of thiazolopyridines, their preparation and pharmaceutical preparations containing them | |
| GB201915831D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| GB201708500D0 (en) | Oral care composition, process for preparation and method of use thereof | |
| GB201915829D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| ZA202104261B (en) | Combination pharmaceutical compositions and methods thereof |